The global microbiome therapeutics market is estimated to garner a revenue of ~USD 4620 Million by the end of 2035 by growing at a CAGR of ~24% over the forecast period, i.e., 2023 – 2035. Further, the market generated a revenue of ~USD 350 Million in the year 2022. The growth of the market can be attributed to the increasing proportion of several diseases comprising inflammatory bowel disease (IBD), obesity, allergic disorders, and so on caused by dysbiosis of microbiota in the gut throughout the world. For instance, currently, there are nearly 11 million individuals have been suffering from inflammatory bowel disease (IBD) across the globe. Further, the growing concerns amongst individuals about the beneficial microorganisms in the human body, growing age, and unhealthy lifestyle patterns are further factors that are projected to drive the global microbiome therapeutics market over the forecast period.
In addition to these, factors that are believed to proliferate the growth of the global microbiome therapeutics market include the radically rising investments in microbiome modulators, and escalating collaboration between major key players for producing novel microbiome therapeutics are also anticipated to fuel market growth in the coming years. For instance, on February 1, 2023, The University of Texas MD Anderson Cancer Center announced a strategic partnership with the global biopharma institute Federation Bio to rationally produce a novel microbiome treatment for immunotherapy-resistant cancer patients. Additionally, the surging awareness regarding microbiome therapeutics is also predicted to present the potential for market expansion over the projected period.
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~24% |
|
Base Year Market Size (2022) |
~ USD 350 Million |
|
Forecast Year Market Size (2035) |
~ USD 4620 Million |
|
Regional Scope |
|
Growth Drivers
Worldwide Growing Prevalence of Diabetes – Diabetes is a chronic disorder that arises when the pancreas does not make enough insulin or when the body does not use the insulin adequately that is produced. The gut microbiota has been related to the development of several metabolic syndromes including diabetes through reduced glucose tolerance and insulin sensitivity. Hence, the rising prevalence of diabetes is estimated to propel the growth of the market over the forecast period. For instance, in 2021, diabetes affected around 540 million individuals throughout the world. Moreover, by 2030, this figure is expected to climb to nearly 648 million.
An Upsurge in Obesity - Obesity is a complicated condition defined by an excess of body fat. It's a medical condition that escalates the chance of getting other diseases and health issues, including heart disease, high blood pressure, and some sort of cancer. The gut microbiota may induce obesity through a multitude of processes, comprising energy balance control, LPS-stimulated inflammation, bile acids, and fat deposition control. Hence, the surge in obesity is anticipated to propel market growth in the coming years. As per the World Health Organization (WHO) figures, obesity affected more than 1 billion people across the globe by 2022, comprising 650 million adults, 340 million adolescents, and 39 million children.
Increasing Ratio of Autoimmune Diseases – Globally, the ratio of several kinds of autoimmune disorders such as celiac disease, Addison disease, multiple sclerosis, and so on has been growing. Any changes in the microbiota of the gastrointestinal tract have been correlated to autoimmune disorders. Thus, the surge in autoimmune diseases is projected to drive the growth of the market. For instance, currently, autoimmune disorders affecting around 24 million individuals in the United States, with women accounting for roughly 82% of those who are affected.
An Increase in the Development of Novel Microbiome – For instance, Persephone Biosciences Inc. began developing an immune-boosting microbiome therapeutic to help mitigate and fight the novel coronavirus (SARS-CoV-2) in April 2020, as well as a potential stool-based diagnostic test to assist in determining which patients are at the greatest chance of suffering from serious medical problems and mortality after suffering from COVID-19.
Rising Healthcare Expenditure - According to World Bank figures, worldwide healthcare expenditure increased by 9.83% in 2019.
Challenges
The global microbiome therapeutics market is segmented and analyzed for demand and supply by application into diabetes, crohn’s disease, clostridium difficile infection (CDI), multiple sclerosis, rheumatoid arthritis, and others. Out of these segments, the diabetes segment is estimated to gain the largest market share of about ~30% in the year 2035. The growth of the segment can be attributed to the increasing prevalence of diabetes around the globe, coupled with the growing research and developments on the use of microbiome therapeutics for curing type 2 diabetes. According to the statistics by the Centers for Disease Control and Prevention (CDC), by the year 2022, around 37.3 million of the population of the United States had diabetes. Studies have reflected that gut bacteria play a fundamental role in diseases such as diabetes, especially type 2 diabetes. Type 2 diabetes is largely undiagnosed and is caused as of excessive body weight and physical inactivity. Research on the first human metagenome demonstrated the correlation between certain bacterial genes, specific intestinal bacteria, and their respective metabolic pathways with type 2 diabetes (T2D).
The global microbiome therapeutics market is also segmented and analyzed for demand and supply by product into prebiotics, probiotics, symbiotics, and others. Amongst these four segments, the probiotics segment is expected to garner a significant share of about ~40% in the year 2035. The growth of the segment can be attributed to the significant advantages of probiotics in the improvement of intestinal health, coupled with the improvement of lactose intolerance symptoms and the decrease of the risk of numerous other diseases. Probiotics are live good bacteria or yeasts that naturally exist in our body and are hugely advantageous for gut health. They aid in the maintenance of a healthy microorganism community in our body. Hence, currently, individuals are inclined to take probiotics for the benefit of digestive health. For instance, based on a consumer survey report, nearly 1/3 of individuals in the United States were keenly trying to consume probiotics, out of which around 61% were trying to use them on daily basis, and around 26% were trying to consume them several times within a day. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years.
Our in-depth analysis of the global microbiome therapeutics market includes the following segments:
|
By Type |
|
|
By Application |
|
|
By Product |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this Report
The North American microbiome therapeutics market, amongst the market in all the other regions, is projected to hold the largest market share of about ~40% by the end of 2035. The growth of the market can be attributed majorly to the significant presence of numerous established research facilities in the region for the development of novel therapeutics, followed by the rising healthcare expenditure and the presence of a population who are highly conscious of their health. Based on the figures provided by the Center for Medicine and Medicaid Services (CMS), In 2021, healthcare spending in the United States increased by 2.7% to USD 4.3 trillion, or USD 12,914 per person. This healthcare expenditure accounted for 18.3% of the nation's gross domestic product. Further, the huge surge in the proportion of aged people, as well as the rise in the requirement for crohn’s disease treatment is also a significant factor that is estimated to radically proliferate the market growth further during the forecast period in the region.
The European microbiome therapeutics market, amongst the market in all the other regions, is projected to hold the second largest share of about ~29% during the forecast period. The growth of the market can be attributed majorly to the presence of well-established research centers along with advantageous reimbursement policies. In addition to this, increasing approval for novel medications, and the huge ratio of investments received by start-ups for the research and development of microbiome-based products is another significant factor that is projected to propel the market growth further throughout the forecast period in the region.
Further, the market in the Asia Pacific region, amongst the market in all the other regions, is projected to hold a considerable share of about ~14% by the end of 2035. The growth of the market can be attributed majorly to the escalating occurrence of inflammatory bowel disease, followed by the surge in diabetes cases in the region. In addition to this, rising initiatives for biological research in various countries in the region, coupled with the escalating awareness about novel therapeutics are also estimated to drive market growth further throughout the forecast period in the region.
Enterome has introduced the world's first clinical data with EO2401, its first-in-class off-the-shelf OncoMimics therapeutic cancer vaccine, at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Ferring International Center S.A. has received approval from the U.S. FDA for REBYOTA (fecal microbiota, live-jslm). It is a novel first-in-class microbiota-based live biotherapeutic denoted for the inhibition of recurrence of Clostridioides difficile infection (CDI) in individuals of 18 years of age and older, following antibiotic treatment for recurrent CDI.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: Rise in the investments of microbiome modulators, worldwide growing prevalence of diabetes, and an increase in the development of novel microbiome are the major factors driving the market growth.
Ans: The market is anticipated to attain a CAGR of ~24% over the forecast period, i.e., 2023 – 2035.
Ans: Risk of failure of the concerned research projects, and stringent regulatory guidelines imposed by the government of nations are estimated to be the growth hindering factors for the market expansion.
Ans: The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Ans: The major players in the market are YSOPIA Bioscience, 4D pharma plc, Enterome, BiomX Inc., Ferring International Center S.A., Vedanta Biosciences, Inc., Seres Therapeutics, Inc., Finch Therapeutics Group, Inc., and others.
Ans: The company profiles are selected based on the revenues generated from segments, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by type, application, product, and by region.
Ans: The diabetes segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?